SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
Module 4: PH7, PH8
Agranular CD4+ natural killer cell leukemia
Agranular CD4+CD56+ hematodermic neoplasm/tumor
Blastic natural killer leukemia/lymphoma
Blastic NK-cell lymphoma [OBS]
Malignant lymphoma, convoluted cell [OBS]
Mlalignant lymphoma, lymphoblastic, NOS
Monomorphic NK-cell lymphoma
Precursor cell lymphoblastic lymphoma, NOS
Until recently, the designation of lymphoblastic lymphoma was used to describe precursor B- and T-cell tumors with predominant lymph node involvement. Most LBL are tumors of precursor T lymphocytes. LBL is composed of medium-sized cells with finely dispersed chromatin and little cytoplasm with inconspicuous nucleoli.
Rare type of hematopoietic neoplasm. Most patients are elderly, but it can occur at any age, including childhood. This neoplasm tends to involve multiple sites: skin (almost 100% of cases), bone marrow and peripheral blood (60%-90%), and nodes (40%-50%). Patients usually present with symptomatic solitary or multiple skin lesions that can be nodules, plaques, or bruising. Bone marrow involvement can be minimal at presentation but invariably develops with progression of disease. Following initial response to chemotherapy, relapses invariably occur involving skin alone or associated with other sites including soft tissue and the central nervous system.